Price$25.05-0.54 (-2.09%)
01:30 PM07:45 PM
News · 26 weeks143-19%
2026-01-182026-07-12
Mix7190d
- Other29(41%)
- Insider26(37%)
- SEC Filings8(11%)
- Dividends4(6%)
- Earnings2(3%)
- Analyst2(3%)
Latest news
25 items- INSIDERSEC Form 4 filed by Chairman & CEO Bourla Albert4 - PFIZER INC (0000078003) (Issuer)
- PRAM Best Affirms Credit Ratings of Blue Whale Re Ltd.AM Best has affirmed the Financial Strength Rating of A (Excellent) and the Long-Term Issuer Credit Rating of "a+" (Excellent) of Blue Whale Re Ltd. (Blue Whale) (Burlington, VT). The outlook of these Credit Ratings (ratings) is stable.The ratings reflect Blue Whale’s balance sheet strength, which AM Best assesses as very strong, as well as its strong operating performance, neutral business profile and appropriate enterprise risk management (ERM).The ratings also reflect Blue Whale’s function as the only captive insurer for Pfizer Inc. (Pfizer) (NYSE:PFE), a global pharmaceutical company. As Blue Whale insures or reinsures Pfizer’s international employee benefits and global property exposure
- INSIDERSEC Form 4 filed by Chairman & CEO Bourla Albert4 - PFIZER INC (0000078003) (Issuer)
- PRU.S. FDA Approves PADCEV® plus Keytruda® as Neoadjuvant and Adjuvant Treatment for Muscle-Invasive Bladder Cancer Regardless of Cisplatin EligibilityFirst and only treatment regimen for adults with MIBC, regardless of cisplatin eligibility, representing a platinum-free potential standard of care Broadened approval supported by Phase 3 EV-304 data showing a nearly 50% reduction in the risk of tumor recurrence, progression or death, and a 35% reduction in the risk of death, versus standard of care in cisplatin-eligible patients Pfizer Inc. (NYSE:PFE) and Astellas Pharma Inc. (TSE: 4503, President and CEO: Naoki Okamura, "Astellas") today announced that the U.S. Food and Drug Administration (FDA) has approved PADCEV® (enfortumab vedotin-ejfv), a Nectin-4 directed antibody-drug conjugate, plus the PD-1 inhibitor, Keytruda® (pembro
- ANALYSTPfizer downgraded by HSBC Securities with a new price targetHSBC Securities downgraded Pfizer from Buy to Hold and set a new price target of $28.00
- INSIDERSEC Form 4 filed by Chairman & CEO Bourla Albert4 - PFIZER INC (0000078003) (Issuer)
- INSIDERSEC Form 4 filed by Director Buckley Mortimer J4 - PFIZER INC (0000078003) (Issuer)
- INSIDERSEC Form 4 filed by Director Echevarria Joseph4 - PFIZER INC (0000078003) (Issuer)
- INSIDERSEC Form 4 filed by Director Narayen Shantanu4 - PFIZER INC (0000078003) (Issuer)
- INSIDERSEC Form 4 filed by Director Smith James C4 - PFIZER INC (0000078003) (Issuer)
- INSIDERSEC Form 4 filed by Director Quincey James4 - PFIZER INC (0000078003) (Issuer)
- INSIDERSEC Form 4 filed by Director Taraporevala Cyrus4 - PFIZER INC (0000078003) (Issuer)
- PRPfizer Declares Third-Quarter 2026 DividendBoard of Directors approves quarterly cash dividend of $0.43 per share Pfizer Inc. (NYSE:PFE) today announced that its board of directors declared a $0.43 third-quarter 2026 dividend on the company’s common stock, payable September 1, 2026, to holders of the Common Stock of record at the close of business on July 24, 2026. Pfizer is committed to maintaining, and over the longer term, growing the dividend, as part of its capital allocation strategy. The third-quarter 2026 cash dividend will be the 351st consecutive quarterly dividend paid by Pfizer. About Pfizer: Breakthroughs That Change Patients’ Lives At Pfizer, we apply science and our global resources to bring therapies to people
- PRFDA Approves Pfizer’s IBRANCE Regimen for HR+, HER2+ Metastatic Breast Cancer Frontline MaintenanceFirst and only CDK4/6 inhibitor approved for HR+ metastatic disease regardless of HER2 status Approval based on data from the collaborative Phase 3 PATINA trial, which showed a 24% risk reduction in disease progression for IBRANCE added to anti-HER2 and endocrine therapies Continues decade-long legacy of IBRANCE helping transform the treatment for HR+ metastatic breast cancer Pfizer Inc. (NYSE:PFE) today announced the U.S. Food and Drug Administration (FDA) approved IBRANCE® (palbociclib) in combination with trastuzumab, with or without pertuzumab, and endocrine therapy for the maintenance treatment of adult patients with hormone receptor-positive (HR+), human epidermal growth fac
- PRNext-Generation DNA Repair Inhibitors Could Capture Billions in Emerging MarketAUSTIN, Texas, June 24, 2026 (GLOBE NEWSWIRE) -- BioMedWire Editorial Coverage: Oncology research is moving through one of its most active stretches in years. DNA Damage Response ("DDR") inhibitors, a category of drugs that work by blocking cancer cells' capacity to fix their own damaged DNA, are growing well beyond the poly ADP ribose polymerase ("PARP") inhibitor that first defined the category. DDR-inhibiting therapies generated an estimated $7 billion-plus in worldwide sales in 2025, and the wider oncology, diagnostics and precision medicine markets are expected to approach about $750 billion by 2030. A fresh wave of inhibitor classes is now taking shape as the next major opportunity.
- PRPfizer Invites Public to View and Listen to Webcast of August 4 Conference Call with AnalystsPfizer Inc. (NYSE:PFE) invites investors and the general public to view and listen to a webcast of a conference call with investment analysts at 10:00 a.m. EDT on Tuesday, August 4, 2026. The purpose of the call is to provide an update on Pfizer’s results, as reflected in the company’s Second Quarter 2026 Performance Report, to be issued that morning. To view and listen to the webcast and view the Performance Report, visit our web site at www.pfizer.com/investors. Information on accessing and registering for the webcast will be available at www.pfizer.com/investors beginning today. Participants are advised to register in advance of the conference call. You can also listen to the confere
- PRPfizer Announces Topline Phase 3 Results for Sigvotatug Vedotin in Previously Treated Metastatic Non-Squamous Non-Small Cell Lung CancerPfizer Inc. (NYSE:PFE) today announced topline results from the Phase 3 SigVie-002 study (previously known as Be6A Lung-01) evaluating sigvotatug vedotin, an investigational, potential first-in-class integrin beta-6 (IB6) directed antibody-drug conjugate (ADC). The study enrolled adults with locally advanced, unresectable or metastatic non-squamous non-small cell lung cancer (NSCLC) who had received one or more lines of prior therapy. In the overall population, sigvotatug vedotin did not show a statistically significant improvement in the primary endpoint of overall survival (OS) compared to docetaxel. The safety profile of sigvotatug vedotin was manageable and consistent with prior s
- SECPfizer Inc. filed SEC Form 8-K: Regulation FD Disclosure, Financial Statements and Exhibits8-K - PFIZER INC (0000078003) (Filer)
- SECPfizer Inc. filed SEC Form 8-K: Leadership Update, Financial Statements and Exhibits8-K - PFIZER INC (0000078003) (Filer)
- PRPfizer Announces Chief Financial Officer TransitionPfizer Inc. (NYSE:PFE) today announced that Dave Denton, Chief Financial Officer, will step down from his current role and leave the company on August 15 for a professional opportunity outside of the pharmaceutical industry in consumer goods, which he has accepted. The company has named Cecile Guegan, currently Senior Vice President, Finance, Global Biopharmaceutical Business, as Interim Chief Financial Officer, effective August 16, while Pfizer conducts a comprehensive internal and external search. Dave and Cecile will work together to ensure a seamless transition. "Dave has been a steady and trusted steward of Pfizer's financial health, and we are grateful for his leadership, especially
- INSIDERSEC Form 4 filed by Chairman & CEO Bourla Albert4 - PFIZER INC (0000078003) (Issuer)
- SECSEC Form 11-K filed by Pfizer Inc.11-K - PFIZER INC (0000078003) (Filer)
- SECSEC Form 11-K filed by Pfizer Inc.11-K - PFIZER INC (0000078003) (Filer)
- INSIDERSVP & Controller Damico Jennifer B. sold $51,400 worth of shares (2,000 units at $25.70), decreasing direct ownership by 6% to 31,397 units (SEC Form 4)4 - PFIZER INC (0000078003) (Issuer)
- ANALYSTPfizer upgraded by RBC Capital Mkts with a new price targetRBC Capital Mkts upgraded Pfizer from Underperform to Sector Perform and set a new price target of $25.00
PFE FAQ
7 questionsWhat does Pfizer Inc. do?
Pfizer Inc. discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. It offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic and pain under the Eliquis, Chantix/Champix, and Premarin family brands; biologics, small molecules, immunotherapies, and biosimilars under the Ibrance, Xtandi, Sutent, Inlyta, Retacrit, Lorbrena, and Braftovi brands; and sterile injectable and anti-infective medicines under the Sulperazon, Medrol, Zithromax, Vfend, and Panzyga brands. The company also provides medicines and...Where does PFE stock trade?
Pfizer Inc. (PFE) is listed on NYSE.What sector and industry is PFE in?
Pfizer Inc. operates in the Health Care sector, Biotechnology: Pharmaceutical Preparations industry.Does PFE pay a dividend?
Yes. PFE's next ex-dividend date is 2026-07-24 with a declared cash dividend of $0.43 per share, payable 2026-09-01.What are analysts saying about PFE?
Pfizer Inc. has had 8 recent analyst actions on file. The most recent action was from HSBC Securities: Hold with a $2800.00 price target on 2026-07-06. Recent price targets range from $2500.00 to $3500.00.What companies are similar to PFE?
Notable peers in the same industry include JNJ (Johnson & Johnson), MRK (Merck & Company Inc.), NVS (Novartis AG), AZN (AstraZeneca PLC), SNY (Sanofi). Compare PFE side-by-side with any of them on Quantisnow.How can I track PFE on Quantisnow?
Quantisnow aggregates Pfizer Inc.'s SEC filings, analyst ratings, insider transactions, FDA approvals, and press releases the moment they hit the wire (Wall Street's wire, on your screen.). Follow PFE to receive live email and push alerts on every new disclosure.